NASDAQ:ARGXargenx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding argenx SE - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$216.11MA: $240.13▼$272.5152-Week Range N/AVolume127,108 shsAverage Volume189,605 shsMarket Capitalization$10.85 billionP/E RatioN/ADividend YieldN/ABeta1.16 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus Ratingargenx has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $225.06, argenx has a potential upside of ∞ from its current price of $0.00.Amount of Analyst Coverageargenx has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform Votesargenx has received 493 “outperform” votes. (Add your “outperform” vote.)Underperform Votesargenx has received 486 “underperform” votes. (Add your “underperform” vote.)Community Sentimentargenx has received 50.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote “Outperform” if you believe ARGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend Yieldargenx does not currently pay a dividend.Dividend Growthargenx does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, argenx insiders have not sold or bought any company stock.Percentage Held by Institutions49.64% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for argenx are expected to decrease in the coming year, from ($10.62) to ($11.38) per share. Previous Next Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARGX Previous Symbol CUSIPN/A CIK1697862 Webwww.argenx.com Phone329-310-3400Debt Debt-to-Equity RatioN/A Current Ratio9.90 Quick Ratio9.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$78.17 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$30.88 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees103 Outstanding Shares47,010,000Market Cap$10.85 billion Next Earnings DateN/A OptionableOptionable 30 days | 90 days | 365 days | Advanced Chart Receive ARGX News and Ratings via Email Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. argenx (NASDAQ:ARGX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of argenx? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for argenx. How were argenx's earnings last quarter? argenx SE - (NASDAQ:ARGX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.72) by $0.15. The firm had revenue of $21.15 million for the quarter, compared to analysts' expectations of $18.08 million. View argenx's earnings history. What price target have analysts set for ARGX? 18 brokers have issued twelve-month target prices for argenx's stock. Their forecasts range from $125.00 to $281.00. On average, they anticipate argenx's stock price to reach $225.06 in the next year. View analysts' price targets for argenx. Has argenx been receiving favorable news coverage? Media headlines about ARGX stock have been trending positive recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. argenx earned a media sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about argenx. Are investors shorting argenx? argenx saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,010,000 shares, an increase of 14.2% from the December 31st total of 884,500 shares. Based on an average daily trading volume, of 168,900 shares, the short-interest ratio is currently 6.0 days. View argenx's Short Interest. Who are some of argenx's key competitors? Some companies that are related to argenx include Moderna (MRNA), Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), Novavax (NVAX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Sorrento Therapeutics (SRNE) and Spark Therapeutics (ONCE). View all competitors. What other stocks do shareholders of argenx own? Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include GALAPAGOS NV/S (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Crispr Therapeutics (CRSP), Beigene (BGNE), Fate Therapeutics (FATE), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Netflix (NFLX) and GW Pharmaceuticals PLC- (GWPH). Who are argenx's key executives? argenx's management team includes the following people: Mr. Tim Van Hauwermeiren, CEO & Exec. Director (Age 47)Mr. Eric Castaldi, Chief Financial Officer (Age 55)Prof. Hans de Haard, Chief Scientific Officer (Age 59)Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 55)Dr. Torsten Dreier, Chief Devel. Officer (Age 55) When did argenx IPO? (ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is argenx's stock symbol? argenx trades on the NASDAQ under the ticker symbol "ARGX." Who are argenx's major shareholders? argenx's stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (0.96%), New York State Common Retirement Fund (0.27%), Candriam Luxembourg S.C.A. (0.13%), Fairmount Funds Management LLC (0.11%), TimesSquare Capital Management LLC (0.10%) and Oak Ridge Investments LLC (0.04%). Which major investors are selling argenx stock? ARGX stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Fairmount Funds Management LLC, Oak Ridge Investments LLC, Vident Investment Advisory LLC, Vident Investment Advisory LLC, and UBS Group AG. Which major investors are buying argenx stock? ARGX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Jennison Associates LLC, New York State Common Retirement Fund, Personal CFO Solutions LLC, M&T Bank Corp, OneAscent Financial Services LLC, Virtu Financial LLC, and Seven Eight Capital LP. How do I buy shares of argenx? Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How big of a company is argenx? argenx has a market capitalization of $0.00 and generates $78.17 million in revenue each year. The company earns $-182,520,000.00 in net income (profit) each year or ($4.73) on an earnings per share basis. argenx employs 103 workers across the globe. What is argenx's official website? The official website for argenx is www.argenx.com. How can I contact argenx? argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected] This page was last updated on 8/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
